Trial Profile
A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/tazobactam Compared With Meropenem in Adult Patients with Ventilated Nosocomial Pneumonia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Ceftolozane/tazobactam (Primary) ; Meropenem
- Indications Nosocomial pneumonia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ASPECT-NP
- Sponsors Cubist Pharmaceuticals
- 04 Jul 2022 Results of retrospective subgroup analysis comparing ceftolozane/tazobactam with meropenem for treating HABP/VABP in mechanically ventilated patients, published in the Journal of Antimicrobial Chemotherapy
- 26 Apr 2022 Results of exposure-efficacy analysis evaluating the relationship between plasma exposure of ceftolozane and tazobactam and efficacy endpoints, published in the Antimicrobial Agents and Chemotherapy
- 12 Jan 2022 Results evaluating clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP published in the Journal of Antimicrobial Chemotherapy